Clinical Trial Results:
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of MORAb-003 (farletuzumab) in Combination with Paclitaxel Therapy in Subjects with Platinum-Resistant or Refractory Relapsed Ovarian Cancer
Summary
|
|
EudraCT number |
2008-005449-43 |
Trial protocol |
NL ES BE |
Global completion date |
27 Jan 2012
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v2(current) |
This version publication date |
12 May 2017
|
First version publication date |
01 Jan 2017
|
Other versions |
v1 |
Version creation reason |
|
Summary report(s) |
MORAb-003-003PR MORAb-003-003PR CT.g summary |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.